We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.48 | 1.73% | 28.29 | 28.325 | 27.94 | 27.94 | 59,853,344 | 23:43:41 |
By Robb M. Stewart
Pfizer Inc. said the U.S. Food and Drug Administration has extended the review period for a pair of drug applications, moving the Prescription Drug User Act goal date for both out to early in the third quarter.
The FDA extended its priority review period for Pfizer's new drug application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis, and also extended the review period for supplemental new drug applications for Xeljanz/Xeljanz XR for the treatment of adults with active ankylosing spondylitis by three months, the drug company said Wednesday.
Abrocitinib is an oral small molecule that selectively inhibits Janus kinase 1, inhibition of which is thought to modulate multiple cytokines involved in pathophysiology of atopic dermatitis, Pfizer said. Xeljanz is approved in the U.S. in four indications--adults with moderately to severely active rheumatoid arthritis after methotrexate failure, adults with active psoriatic arthritis after disease modifying antirheumatic drug failure, adults with moderately to severely active ulcerative colitis after tumor necrosis factor inhibitor failure, and patients 2 years of age or older with active polyarticular course juvenile idiopathic arthritis.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
April 07, 2021 07:26 ET (11:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions